NCT02223819 - Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 3, 2019

Study Completion Date

July 3, 2019

Conditions

Uveal Melanoma

Interventions

DRUG

Crizotinib

"An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."

Trial Locations (4)

10032

Columbia Univeristy Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

43210

The Ohio State University, Columbus